Losartan and SSRIs (Sertraline, Escitalopram): Drug Interaction Guide

Losartan is an angiotensin II receptor blocker (ARB), sold under the brand name Cozaar, used to treat hypertension and certain kidney and cardiovascular conditions. It is a prodrug, meaning the liver must convert it into an active form to work. Sertraline (Zoloft) and escitalopram (Lexapro) are selective serotonin reuptake inhibitors (SSRIs) used for depression and anxiety disorders. This article covers the oral tablet forms of all three drugs, not compounded or extended-release variants.

Direct answer

Losartan can generally be combined with sertraline or escitalopram. This is not a contraindicated pairing in any major drug interaction database, and neither drug's FDA label restricts co-use. The combination raises two distinct concerns that are mechanistically unrelated: a pharmacokinetic interaction in which SSRIs that inhibit the liver enzyme CYP2C9 may modestly reduce conversion of losartan to its active metabolite, and a pharmacodynamic concern in which SSRIs can independently cause low sodium (hyponatremia) through excess antidiuretic hormone activity, an effect that could theoretically add to losartan's own mild effect on aldosterone. Escitalopram carries a weaker pharmacokinetic interaction than sertraline; both SSRIs carry a similar hyponatremia risk profile, most pronounced in older adults in the first weeks of treatment. Neither drug interaction requires an automatic dose change, but baseline and early follow-up electrolyte checks are reasonable given how the two risks compound in vulnerable patients.

The useful question is not "do they interact" but "which pathway applies to which patient"

Losartan-SSRI questions get treated as a single interaction with a single severity rating. In practice there are two separate mechanisms operating on different timelines, in different patients, with different monitoring responses. Confusing them leads to the wrong response: checking blood pressure when the real risk is sodium, or restricting fluids when the real risk is under-treated hypertension. The rest of this page separates the two pathways and states plainly what is established, what is plausible, and what remains unverified.

Why this combination is common

Hypertension and depression are both common conditions in adults over 50, and treatment for one does not exclude the other. Losartan is one of the more widely prescribed ARBs, and sertraline and escitalopram are among the more commonly prescribed SSRIs. Beyond that general clinical familiarity, we do not have a verified, page-specific prevalence statistic for how often the two drugs are co-prescribed, and a precise co-prescription percentage should not be treated as established without checking the primary source.

Pathway one: CYP2C9 competition and the active metabolite

Losartan itself is a relatively weak AT1 receptor blocker. Most of its antihypertensive effect comes from its active metabolite, EXP-3174 (also called E-3174), which is far more potent at the receptor. The liver enzyme CYP2C9 does most of the work converting losartan into EXP-3174, with a smaller contribution from CYP3A4.

Any drug that inhibits CYP2C9 can, in principle, blunt this conversion and reduce the antihypertensive effect. Among SSRIs, fluoxetine and fluvoxamine are recognized as stronger CYP2C9 inhibitors and pose the more meaningful theoretical risk. Sertraline is generally described in the pharmacology literature as a weak-to-moderate CYP2C9 inhibitor, and escitalopram has minimal CYP2C9 inhibitory activity. This ranking (fluoxetine/fluvoxamine > sertraline > escitalopram) is pharmacologically plausible and consistent with how these drugs are classified in clinical references, but a precise numeric estimate of how much sertraline reduces EXP-3174 exposure in practice requires verification against the primary pharmacokinetic literature before it should be quoted to a patient or written into a chart note.

CYP2C9 poor metabolizers, a genetically defined minority of patients who carry two reduced-function CYP2C9 alleles, already convert less losartan to its active form. In this smaller subgroup, adding even a weak inhibitor could matter more than it would in a typical metabolizer. This is a plausible, biologically coherent concern rather than a proven clinical outcome, since dedicated outcome data in poor metabolizers taking losartan plus an SSRI does not appear to be established in the literature available for this review.

What this means practically: if blood pressure that was previously well controlled on losartan rises meaningfully after starting sertraline (less so with escitalopram), the CYP2C9 pathway is a reasonable explanation to consider, alongside more common causes like dietary sodium, adherence, or a new NSAID.

Pathway two: additive hyponatremia risk

SSRIs are an established cause of the syndrome of inappropriate antidiuretic hormone secretion (SIADH), which can lower blood sodium. This is a recognized class effect described in pharmacology references and case literature, and the risk is understood to be highest in the first weeks after starting or increasing an SSRI dose, and greater in older adults. Whether escitalopram and sertraline differ meaningfully from each other in hyponatremia risk is not something this review can confirm with a verified head-to-head source; both should be treated as carrying the risk.

Losartan blocks angiotensin II, which in turn reduces aldosterone secretion. Reduced aldosterone can modestly impair sodium retention, though clinically significant hyponatremia from an ARB alone is uncommon. The concern with combining losartan and an SSRI is additive risk: one drug promoting water retention through ADH, the other mildly reducing sodium retention through aldosterone suppression. This combined mechanism is biologically plausible and is the rationale most clinical references give for recommending sodium monitoring, but a precise quantified increase in hyponatremia risk specific to the losartan-SSRI pairing (as opposed to SSRIs generally, or antihypertensives generally) is not established from the sources available here and should not be cited as a specific multiplier.

Older adults, patients also taking a thiazide diuretic (including combination products like losartan/hydrochlorothiazide), and patients with heart failure or cirrhosis are the groups where this additive risk is most clinically relevant, because they already have less physiologic reserve to compensate for sodium shifts.

Symptoms of hyponatremia include headache, nausea, confusion, unusual fatigue, and muscle cramps, with seizures possible in severe cases. These symptoms overlap with common early SSRI side effects, which is exactly why they are easy to miss without a lab check.

Serotonin syndrome is not the relevant concern here

Serotonin syndrome requires excess serotonergic activity from two or more drugs acting through different mechanisms. Losartan has no serotonergic activity: it does not inhibit serotonin reuptake, does not act on serotonin receptors, and does not inhibit monoamine oxidase. Adding losartan to an SSRI does not increase serotonin syndrome risk. This distinguishes the losartan-SSRI pairing from genuinely serotonergic combinations, such as an SSRI plus tramadol, a triptan, or an MAOI, which carry a real and separate risk that is outside the scope of this page.

Where major references place this interaction

Commercial drug interaction databases (such as those used by pharmacies and electronic health records) generally classify losartan-SSRI pairs at a low-to-moderate severity tier, often described as "monitor therapy" rather than "avoid" or "contraindicated," with sertraline typically flagged more prominently than escitalopram because of its CYP2C9 activity. No major database or the FDA-approved prescribing information for either drug lists this combination as contraindicated. That said, the exact wording and severity tier assigned by any specific database is proprietary and can change between updates; clinicians and pharmacists checking a specific patient's chart should verify current classification in their own reference tool rather than relying on a general description here.

The FDA-approved labeling for losartan describes its CYP2C9-dependent metabolism to EXP-3174 as part of its clinical pharmacology, and the FDA-approved labeling for sertraline describes its CYP2C9 inhibitory activity as a general pharmacologic property; neither label specifically names the other drug as a required dose-adjustment interaction. Current label language should be checked directly through Drugs@FDA rather than assumed from this summary, since labels are updated periodically.

Evidence-status interaction assessment

What to verify before treating a specific patient

• Confirm the patient's specific SSRI and dose; fluoxetine and fluvoxamine warrant more caution than sertraline or escitalopram.
• Check baseline sodium, potassium, and kidney function before starting the combination if the patient has other hyponatremia risk factors (age over 65, thiazide use, heart failure, cirrhosis, low baseline sodium).
• Recheck sodium within the first few weeks of SSRI initiation in higher-risk patients; this window is when SIADH-related hyponatremia is most likely to appear.
• Reassess blood pressure after SSRI initiation in patients previously well controlled on losartan, particularly with sertraline; rule out non-interaction causes (diet, adherence, NSAID use) before attributing a change to the drug interaction.
• Consult the current FDA labeling and your institution's drug interaction database for the most current severity classification, since these are updated periodically and were not independently re-verified line by line for this article.
• If a patient is a known or suspected CYP2C9 poor metabolizer, or has recurrent hyponatremia, discuss alternatives (an ARB that is not a prodrug, such as valsartan or olmesartan, or an antidepressant with a different risk profile) with the prescriber rather than adjusting doses independently.

Alternatives worth knowing about

Valsartan, olmesartan, and azilsartan are ARBs that are active on their own and do not require CYP2C9 activation, which removes the pharmacokinetic pathway described above (though not the separate hyponatremia concern, which comes from the SSRI). Telmisartan is metabolized mainly by glucuronidation rather than CYP enzymes. Among antidepressants, bupropion and mirtazapine are generally described as carrying lower hyponatremia risk than SSRIs, which is one reason they are sometimes considered in patients with known electrolyte vulnerability; this is a general clinical pattern rather than a claim this article can quantify precisely, and the choice of antidepressant belongs to the prescribing clinician weighing the patient's psychiatric needs, not to this interaction guide.

When to seek urgent care

New confusion, seizures, severe weakness, or fainting in a patient on this combination warrants urgent evaluation rather than waiting for a routine follow-up appointment, since these can be signs of significant hyponatremia. Chest pain, severe dizziness with fainting, or a large unexplained drop or spike in blood pressure also warrant prompt medical attention.

What this page does not establish

This page describes mechanism-based reasoning and general classifications from pharmacology references and drug interaction databases. It does not provide a verified quantitative estimate of how much sertraline reduces losartan's effectiveness in real-world patients, a verified comparative hyponatremia risk between sertraline and escitalopram, or a verified outcome study specific to CYP2C9 poor metabolizers taking losartan with an SSRI. Any of these numbers, if needed for a specific clinical decision, should be confirmed against current primary literature or an up-to-date pharmacy reference rather than taken from this summary. This article is educational and does not substitute for individualized advice from a prescribing clinician or pharmacist, who can account for a patient's specific labs, other medications, and comorbidities.